KRIBIOLISA™ Zalifrelimab ELISA

SKU: KBI1742 Category:

₹58,000.00

Enzyme Immunoassay for the estimation of Zalifrelimab in serum and plasma.

About the kit:
– Uses anti-idiotypic monoclonal antibodies which ensures higher specificity, and low cross reactivity.
– Recovery rates are between 85 – 115%
– Validated as per US FDA guidelines for Bioassays
– Precision CV<10%


Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells

Add to wishlist

Description

Background:
Zalifrelimab (AGEN1884) is a fully humanIgG1monoclonal antibody targetingCTLA-4(CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated byCTLA-4signaling.

Intended Use:
For Estimation of Zalifrelimab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.









If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)
Calibration Range

0 ng/ml – 2000 ng/ml
Specificity

80% – 120% to Zalifrelimab
Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.
Interference

No significant interference observed with available related molecules.
Regulatory Status

Research Use Only
Research Area

Biosimilars / Therapeutic Drug Monitoring
Entez Gene ID

AGEN-1884 Human
Alternate Names / Synonyms

Zalifrelimab
Validation

The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer the IFU for more details.
Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.
Long Name

Protein Based Therapies – Monoclonal Antibody

Related products